Wang Yanhong, Ouyang Yi, Chen Yiping, Bai Zhigang, Cao Xinping, Cai Qunrong, Xu Qin
Department of Radiation Oncology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
Front Med (Lausanne). 2025 Jun 20;12:1606685. doi: 10.3389/fmed.2025.1606685. eCollection 2025.
Clear cell adenocarcinoma of the cervix (CCAC) is a rare malignancy without a well-established prognostic model. Our study aimed to develop and validate a nomogram to estimate overall survival in CCAC patients.
We collected data on 630 CCAC patients from the Surveillance, Epidemiology, and End Results (SEER) database (2000-2021). Missing clinicopathological data were imputed using the missForest package. The imputed dataset served as the training cohort, while the dataset with missing values removed acted as the validation cohort. The nomogram's performance was assessed through discriminative ability, calibration, C-index, AUC, and calibration plots. Clinical benefits were compared against the International Federation of Gynecology and Obstetrics (FIGO) staging using decision curve analysis (DCA), net reclassification index (NRI), and integrated discrimination improvement (IDI).
The nomogram, based on nine variables, demonstrated strong discriminative power, with C-index values of 0.82 for the training cohort and 0.81 for the validation cohort, and AUCs exceeding 0.80 in both sets. Calibration plots showed a strong agreement between the nomogram's predictions and actual outcomes in both cohorts. The NRI values for the training set were 0.21 for 3-year, 0.20 for 5-year, and 0.30 for 10-year overall survival (OS) predictions, and for the validation set were 0.34 for 3-year, 0.25 for 5-year, and 0.31 for 10-year OS predictions. The IDI results for the training set were 0.17 across 3-, 5-, and 10-year OS predictions, and for the validation set were 0.21 for 3-year, 0.17 for 5-year, and 0.15 for 10-year OS predictions. The nomogram significantly outperformed the FIGO criteria ( < 0.01), and DCA highlighted its superior clinical utility in identifying high-risk patients.
The nomogram, which integrates treatment data, was successfully developed and validated to assist clinicians in assessing the prognosis of CCAC patients. It demonstrated superior performance to FIGO criteria in predicting overall survival.
宫颈透明细胞腺癌(CCAC)是一种罕见的恶性肿瘤,尚无成熟的预后模型。我们的研究旨在开发并验证一种列线图,以评估CCAC患者的总生存期。
我们从监测、流行病学和最终结果(SEER)数据库(2000 - 2021年)收集了630例CCAC患者的数据。使用missForest软件包估算缺失的临床病理数据。估算后的数据集作为训练队列,而去除缺失值的数据集作为验证队列。通过判别能力、校准、C指数、AUC和校准图评估列线图的性能。使用决策曲线分析(DCA)、净重新分类指数(NRI)和综合判别改善(IDI)将临床获益与国际妇产科联盟(FIGO)分期进行比较。
基于九个变量的列线图显示出强大的判别能力,训练队列的C指数值为0.82,验证队列的C指数值为0.81,两组的AUC均超过0.80。校准图显示,两个队列中列线图的预测结果与实际结果高度一致。训练集3年总生存期(OS)预测的NRI值为0.21,5年为0.20,10年为0.30;验证集3年OS预测的NRI值为0.34,5年为0.25,10年为0.31。训练集3年、5年和10年OS预测的IDI结果均为0.17;验证集3年OS预测的IDI值为0.21,5年为0.17,10年为0.15。列线图显著优于FIGO标准(P < 0.01),DCA突出了其在识别高危患者方面的卓越临床效用。
整合了治疗数据的列线图已成功开发并验证,可协助临床医生评估CCAC患者的预后。在预测总生存期方面,它表现出优于FIGO标准的性能。